Staying Abreast of New Biomarkers in Hematology/Oncology

J Adv Pract Oncol. 2024 Apr;15(3):164-169. doi: 10.6004/jadpro.2024.15.3.2. Epub 2024 Apr 1.

Abstract

There has been an increasing number of approvals for targeted therapies in oncology in the past decade, changing the treatment paradigm for many solid tumors and hematologic malignancies. At JADPRO Live 2023, presenters provided an in-depth review of cancer biomarkers, including testing methodology, recommended therapies, and how advanced practitioners can integrate results into clinical decision-making.